{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Metastatic+Cervical+Cancer&page=11",
    "query": {
      "condition": "Metastatic Cervical Cancer",
      "page": 11
    },
    "page_size": 10
  },
  "pagination": {
    "page": 11,
    "page_size": 10,
    "total_count": 1072,
    "total_pages": 108,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Metastatic+Cervical+Cancer&page=12&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Metastatic+Cervical+Cancer&page=10&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-06T19:27:45.848Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03646461",
      "title": "Trial of Ibrutinib Combined With Nivolumab or Cetuximab to Treat Recurrent/Metastatic HNSCC",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Head and Neck Cancer",
        "Squamous Cell Carcinoma of the Head and Neck"
      ],
      "interventions": [
        {
          "name": "Ibrutinib 560mg PO daily (Imbruvica)",
          "type": "DRUG"
        },
        {
          "name": "Cetuximab",
          "type": "DRUG"
        },
        {
          "name": "Nivolumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of California, San Diego",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 5,
      "start_date": "2018-10-17",
      "completion_date": "2021-05-13",
      "has_results": true,
      "last_update_posted_date": "2026-05-22",
      "last_synced_at": "2026-11-06T19:27:45.848Z",
      "location_count": 1,
      "location_summary": "La Jolla, California",
      "locations": [
        {
          "city": "La Jolla",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03646461"
    },
    {
      "nct_id": "NCT06046482",
      "title": "Phase II Trial of Magrolimab and Cetuximab With Pembrolizumab or Docetaxel for Recurrent/Metastatic Head Neck Squamous Cell Carcinoma",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Head Neck",
        "Squamous Cell Carcinoma of Head and Neck"
      ],
      "interventions": [
        {
          "name": "Pembrolizumab",
          "type": "DRUG"
        },
        {
          "name": "Magrolimab",
          "type": "DRUG"
        },
        {
          "name": "cetuximab",
          "type": "DRUG"
        },
        {
          "name": "Docetaxel",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 4,
      "start_date": "2023-11-28",
      "completion_date": "2024-08-26",
      "has_results": true,
      "last_update_posted_date": "2025-10-22",
      "last_synced_at": "2026-11-06T19:27:45.848Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06046482"
    },
    {
      "nct_id": "NCT04579380",
      "title": "Basket Study of Tucatinib and Trastuzumab in Solid Tumors With HER2 Alterations",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Uterine Neoplasms",
        "Uterine Cervical Neoplasms",
        "Biliary Tract Neoplasms",
        "Urologic Neoplasms",
        "Carcinoma, Non-Small-Cell Lung",
        "HER2 Mutations Breast Neoplasms"
      ],
      "interventions": [
        {
          "name": "tucatinib",
          "type": "DRUG"
        },
        {
          "name": "trastuzumab",
          "type": "DRUG"
        },
        {
          "name": "fulvestrant",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Seagen, a wholly owned subsidiary of Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 217,
      "start_date": "2021-01-11",
      "completion_date": "2026-12-31",
      "has_results": true,
      "last_update_posted_date": "2026-08-21",
      "last_synced_at": "2026-11-06T19:27:45.848Z",
      "location_count": 76,
      "location_summary": "Phoenix, Arizona • Tempe, Arizona • Tucson, Arizona + 47 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tempe",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Huntington Beach",
          "state": "California"
        },
        {
          "city": "Irvine",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04579380"
    },
    {
      "nct_id": "NCT06349642",
      "title": "Immune Checkpoint Inhibitor Response in Solid Tumors Using a Live Tumor Diagnostic Platform",
      "overall_status": "RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Early Stage Triple-Negative Breast Carcinoma",
        "Metastatic Bladder Urothelial Carcinoma",
        "Metastatic Cervical Carcinoma",
        "Metastatic Clear Cell Renal Cell Carcinoma",
        "Metastatic Colorectal Carcinoma",
        "Metastatic Endometrial Carcinoma",
        "Metastatic Esophageal Carcinoma",
        "Metastatic Liver Carcinoma",
        "Metastatic Lung Non-Small Cell Carcinoma",
        "Metastatic Malignant Skin Neoplasm",
        "Metastatic Malignant Solid Neoplasm",
        "Resectable Lung Non-Small Cell Carcinoma",
        "Early Stage Lung Non-Small Cell Carcinoma",
        "Resectable Malignant Solid Neoplasm",
        "Resectable Triple-Negative Breast Carcinoma",
        "Stage III Renal Cell Cancer AJCC v8",
        "Stage IV Cervical Cancer AJCC v8",
        "Stage IV Renal Cell Cancer AJCC v8",
        "Stage IV Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8",
        "Recurrent Cervical Carcinoma",
        "Recurrent Colorectal Carcinoma",
        "Recurrent Endometrial Carcinoma",
        "Recurrent Esophageal Carcinoma",
        "Recurrent Liver Carcinoma",
        "Recurrent Lung Non-Small Cell Carcinoma",
        "Recurrent Malignant Skin Neoplasm",
        "Recurrent Malignant Solid Neoplasm"
      ],
      "interventions": [
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        },
        {
          "name": "Tissue Collection",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "PROCEDURE"
      ],
      "sponsor": "Mayo Clinic",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 324,
      "start_date": "2024-04-24",
      "completion_date": "2027-05",
      "has_results": false,
      "last_update_posted_date": "2026-03-12",
      "last_synced_at": "2026-11-06T19:27:45.848Z",
      "location_count": 3,
      "location_summary": "Phoenix, Arizona • Jacksonville, Florida • Rochester, Minnesota",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06349642"
    },
    {
      "nct_id": "NCT01577173",
      "title": "A Study of MEHD7945A Versus Cetuximab in Patients With Recurrent/Metastatic Squamous Cell Carcinoma of The Head And Neck",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Head and Neck Cancer"
      ],
      "interventions": [
        {
          "name": "MEHD7945A",
          "type": "DRUG"
        },
        {
          "name": "cetuximab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Genentech, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 122,
      "start_date": "2012-07",
      "completion_date": "2015-06",
      "has_results": false,
      "last_update_posted_date": "2016-11-02",
      "last_synced_at": "2026-11-06T19:27:45.848Z",
      "location_count": 14,
      "location_summary": "Stanford, California • Aurora, Colorado • Miami, Florida + 10 more",
      "locations": [
        {
          "city": "Stanford",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Paducah",
          "state": "Kentucky"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01577173"
    },
    {
      "nct_id": "NCT03543813",
      "title": "PROCLAIM-CX-2029: A Trial to Find Safe and Active Doses of an Investigational Drug CX-2029 for Patients With Solid Tumors or DLBCL",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Solid Tumor, Adult",
        "Head and Neck Cancer",
        "Non Small Cell Lung Cancer",
        "Diffuse Large B Cell Lymphoma",
        "Esophageal Cancer"
      ],
      "interventions": [
        {
          "name": "CX-2029",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "CytomX Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 133,
      "start_date": "2018-06-15",
      "completion_date": "2023-06-01",
      "has_results": false,
      "last_update_posted_date": "2024-01-23",
      "last_synced_at": "2026-11-06T19:27:45.848Z",
      "location_count": 15,
      "location_summary": "Birmingham, Alabama • Encinitas, California • Los Angeles, California + 12 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Encinitas",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Lake Mary",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03543813"
    },
    {
      "nct_id": "NCT05271604",
      "title": "A Phase 2 Open Label Study of BA3021 in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Head and Neck Cancer",
        "Squamous Cell Carcinoma of Head and Neck",
        "Recurrent Squamous Cell Carcinoma of the Head and Neck",
        "Metastatic Cancer",
        "Metastatic Squamous Cell Carcinoma of the Head and Neck"
      ],
      "interventions": [
        {
          "name": "Ozuriftamab Vedotin",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Pembrolizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Evalstotug (BA3071)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Cetuximab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "BioAtla, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 42,
      "start_date": "2022-12-13",
      "completion_date": "2025-09-22",
      "has_results": false,
      "last_update_posted_date": "2025-09-26",
      "last_synced_at": "2026-11-06T19:27:45.848Z",
      "location_count": 7,
      "location_summary": "Los Angeles, California • Newark, Delaware • Chicago, Illinois + 4 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Newark",
          "state": "Delaware"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Louisville",
          "state": "Kentucky"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05271604"
    },
    {
      "nct_id": "NCT00003326",
      "title": "Paclitaxel in Treating Patients With Metastatic, Recurrent, or Unresectable Cancer of the Esophagus",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Esophageal Cancer"
      ],
      "interventions": [
        {
          "name": "paclitaxel",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Theradex",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 100,
      "start_date": "1997-09",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2008-07-24",
      "last_synced_at": "2026-11-06T19:27:45.848Z",
      "location_count": 30,
      "location_summary": "Mobile, Alabama • Loma Linda, California • San Francisco, California + 25 more",
      "locations": [
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Loma Linda",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Fort Myers",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00003326"
    },
    {
      "nct_id": "NCT03127098",
      "title": "QUILT-3.040: ETBX-011 (Ad5 [E1-, E2b-]-CEA(6D)) Vaccine in Combination With ALT-803 (Super-agonist IL-15) in Subjects Having CEA-Expressing Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Thyroid Cancer",
        "Colon Cancer",
        "Ovarian Cancer",
        "Breast Cancer",
        "Lung Cancer",
        "Pancreatic Cancer"
      ],
      "interventions": [
        {
          "name": "ETBX-011",
          "type": "BIOLOGICAL"
        },
        {
          "name": "ALT-803",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "NantCell, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "21 Years and older"
      },
      "enrollment_count": 3,
      "start_date": "2017-06-26",
      "completion_date": "2017-12-07",
      "has_results": true,
      "last_update_posted_date": "2024-08-06",
      "last_synced_at": "2026-11-06T19:27:45.848Z",
      "location_count": 1,
      "location_summary": "Spokane, Washington",
      "locations": [
        {
          "city": "Spokane",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03127098"
    },
    {
      "nct_id": "NCT04106843",
      "title": "Radioactive Drug (177Lu-DOTATATE) for the Treatment of Locally Advanced, Metastatic, or Unresectable Rare Endocrine Cancers",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Locally Advanced Adrenal Gland Pheochromocytoma",
        "Locally Advanced Paraganglioma",
        "Metastatic Adrenal Gland Pheochromocytoma",
        "Metastatic Paraganglioma",
        "Metastatic Parathyroid Gland Carcinoma",
        "Pituitary Gland Carcinoma",
        "Somatostatin Receptor Positive",
        "Stage III Thyroid Gland Medullary Carcinoma AJCC v8",
        "Stage IV Thyroid Gland Medullary Carcinoma AJCC v8",
        "Stage IVA Thyroid Gland Medullary Carcinoma AJCC v8",
        "Stage IVB Thyroid Gland Medullary Carcinoma AJCC v8",
        "Stage IVC Thyroid Gland Medullary Carcinoma AJCC v8",
        "Unresectable Adrenal Gland Pheochromocytoma",
        "Unresectable Paraganglioma"
      ],
      "interventions": [
        {
          "name": "Lutetium Lu 177 Dotatate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2019-06-13",
      "completion_date": "2020-09-03",
      "has_results": false,
      "last_update_posted_date": "2020-09-07",
      "last_synced_at": "2026-11-06T19:27:45.848Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04106843"
    }
  ]
}